GLP-1s like semaglutide are effective for weight loss, but without the right protocol, you may be losing muscle, not just fat. Here’s what to do about it.
The scale is moving. Your clothes fit differently. By every visible measure, the medication is working.
But you’re more tired than you expected. You feel weaker. Less toned. Something about the progress doesn’t feel right, and you’re not sure why.
Here’s what often doesn’t get discussed upfront: the number on the scale doesn’t tell you what you’re losing.
GLP-1 receptor agonists (semaglutide, tirzepatide, and related medications) are genuinely effective tools for reducing appetite and driving weight loss. That part is not in question.
What is less frequently discussed is body composition. Studies on GLP-1 therapy consistently show that a meaningful portion of the weight lost is lean body mass, not just fat. Estimates vary by study and protocol, but roughly 25 to 40 percent of total weight lost on GLP-1 therapy can come from lean mass when the medication is used without intentional muscle preservation strategies.
Of weight lost was lean mass in the body composition substudy[1]
Of weight lost was lean mass in the body composition substudy[2]
DXA “lean mass” includes muscle plus water, organ tissue, and glycogen, so not all of it is muscle. But muscle is a real part of what’s lost, and it’s the part worth protecting.
This is not a reason to avoid GLP-1 therapy. It is a reason to approach it with a complete protocol, not just a prescription.
Muscle is not just about appearance or athletic performance. It is your metabolic engine.
Skeletal muscle is the primary tissue responsible for glucose uptake after meals. When you lose muscle mass, your body becomes less efficient at managing blood sugar, which is one of the core problems GLP-1 therapy is often used to address in the first place. Losing muscle while treating insulin resistance can undermine the very metabolic improvements you’re working toward.
Muscle is a major contributor to your resting metabolic rate. The more lean mass you carry, the more calories your body burns at rest. When GLP-1-driven weight loss includes significant muscle loss, the result is a lower metabolic floor, meaning you need fewer calories to maintain your new weight. That makes maintaining results significantly harder once the medication dose changes or stops.
From a functional medicine perspective, this is one of the most important conversations to have before starting GLP-1 therapy, not after results plateau.
The research is reasonably clear on which interventions preserve lean mass during caloric restriction and GLP-1 therapy: protein intake and resistance training.[3][4]
Current evidence supports a target of 1.2 to 1.6 grams of protein per kilogram of body weight daily for people in active weight loss, particularly on appetite-suppressing medications. GLP-1s reduce hunger significantly, which means patients often undereat protein without realizing it. Hitting protein targets becomes an active effort, not a passive outcome of eating less.
Three sessions per week of progressive resistance training has strong support for preserving lean mass during weight loss. This does not need to be complex or high-volume: compound movements with progressive overload three times weekly is a meaningful stimulus for muscle retention.
Most GLP-1 protocols do not include either of these conversations in a structured way. The prescription is written, appetite drops, weight comes off, and no one maps out how to protect the tissue that determines whether results last.
In functional medicine, GLP-1 therapy is a tool, a powerful one, within a larger protocol that addresses why metabolic dysfunction developed in the first place.
Fasting insulin, HOMA-IR, glucose, HbA1c, a lipid panel with particle size, inflammatory markers, and relevant hormones. These tell us the full picture of what’s driving weight resistance, and where the medication fits in the strategy.
A scale tells you pounds. It doesn’t tell you the ratio of fat to muscle. We track the metrics that actually reflect whether the protocol is working the way it should.
We build in the protein targets, the training structure, and the nutritional framework that keep lean mass protected, so that when weight comes off, it’s the weight that should come off.
That’s the difference between losing weight and losing well.
Download The GLP-1 Lab Checklist and know exactly which labs to run before, during, and after GLP-1 therapy, so you have the full metabolic picture, not just a number on a scale.
Free instant download. No spam, unsubscribe anytime.
If you’re currently on a GLP-1 and haven’t had a conversation about muscle preservation, these are the questions worth asking:
If the answers are mostly no, you’re not doing anything wrong. Most protocols don’t include this. But it’s worth building in now, before the results you’ve worked for are harder to maintain.
If you’re on a GLP-1 and want to build a protocol that protects your muscle, optimizes your labs, and makes results sustainable, a discovery call is the place to start.
Book a Discovery Call →Some lean mass is typically lost along with fat. In the STEP 1 body composition substudy, about 39% of weight lost on semaglutide was lean mass, and in SURMOUNT-1, about 25% of weight lost on tirzepatide was lean mass. Lean mass on these scans includes water and organ tissue as well as muscle.
Skeletal muscle is the primary tissue for glucose uptake after meals and a major contributor to resting metabolic rate. Losing muscle can undermine blood sugar improvements and lower your metabolic floor, which makes results harder to maintain if the medication dose changes or stops.
Current evidence supports 1.2 to 1.6 grams of protein per kilogram of body weight daily during active weight loss. Because GLP-1s reduce appetite, hitting that target usually takes intentional effort.
The two best-supported strategies are adequate protein and progressive resistance training about three times per week. Tracking body composition, not just weight, shows whether the protocol is working.
A fuller metabolic picture can include fasting insulin, HOMA-IR, glucose, HbA1c, a lipid panel with particle size, inflammatory markers, and relevant hormones, rather than weight and A1c alone.
For educational purposes only. Not a diagnosis, and not a substitute for care from your healthcare provider. Do not start, stop, or change any medication without talking with your prescriber.
